SSA
RCKT icon

Schonfeld Strategic Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$378K Buy
+110,666
New +$368K ﹤0.01% 1935
2026
Q1 		– Sell
-149,413
Closed -$524K – 2590
2025
Q4 		$524K Buy
+149,413
New +$512K ﹤0.01% 1376
2025
Q3 		– Sell
-28,362
Closed -$69.5K – 2506
2025
Q2 		$69.5K Buy
28,362
+16,930
+148% +$85.8K ﹤0.01% 1863
2025
Q1 		$76.3K Buy
+11,432
New +$113K ﹤0.01% 2043
2023
Q4 		– Sell
-10,400
Closed -$213K – 2160
2023
Q3 		$213K Sell
10,400
-19,724
-65% -$359K ﹤0.01% 1402
2023
Q2 		$599K Buy
+30,124
New +$609K 0.01% 1150
2023
Q1 		– Sell
-51,024
Closed -$999K – 2541
2022
Q4 		$999K Sell
51,024
-22,488
-31% -$414K 0.01% 1152
2022
Q3 		$1.17M Buy
+73,512
New +$1.15M 0.01% 1165
2022
Q1 		– Sell
-41,400
Closed -$903K – 2866
2021
Q4 		$903K Sell
41,400
-29,870
-42% -$815K 0.01% 988
2021
Q3 		$2.13M Buy
71,270
+35,067
+97% +$1.28M 0.02% 691
2021
Q2 		$1.6M Sell
36,203
-298
-0.8% -$12.9K 0.02% 787
2021
Q1 		$1.62M Sell
36,501
-3,111
-8% -$171K 0.02% 728
2020
Q4 		$2.17M Buy
39,612
+13,591
+52% +$495K 0.03% 580
2020
Q3 		$595K Sell
26,021
-24,934
-49% -$614K 0.01% 860
2020
Q2 		$1.07M Buy
+50,955
New +$919K 0.03% 587
2020
Q1 		– Sell
-36,435
Closed -$829K – 1453
2019
Q4 		$829K Sell
36,435
-39,165
-52% -$654K 0.02% 562
2019
Q3 		$881K Sell
75,600
-107,300
-59% -$1.33M 0.03% 503
2019
Q2 		$2.74M Buy
182,900
+158,300
+643% +$2.76M 0.1% 240
2019
Q1 		$432K Sell
24,600
-77,600
-76% -$1.23M 0.02% 734
2018
Q4 		$1.51M Buy
102,200
+77,200
+309% +$1.28M 0.06% 378
2018
Q3 		$616K Buy
+25,000
New +$542K 0.03% 535
2018
Q2 		– Sell
-24,460
Closed -$459K – 929
2018
Q1 		$459K Buy
+24,460
New +$399K 0.03% 496

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Schonfeld Strategic Advisors's RCKT Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Rocket Pharmaceuticals (RCKT) in Q2 2026: 110,666 shares worth $378K. The stake represents ﹤0.01% of the portfolio and ranks #1935 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in RCKT as recently as Q4 2025.

Schonfeld Strategic Advisors first reported a position in RCKT in Q1 2018 and has held it in 22 quarters since. The position peaked at $2.74M in Q2 2019. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Schonfeld Strategic Advisors held 110,666 shares of Rocket Pharmaceuticals worth $378K as of Q2 2026.
  • Rocket Pharmaceuticals was a new Schonfeld Strategic Advisors position in Q2 2026.
  • Rocket Pharmaceuticals made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #1935 holding.
  • Schonfeld Strategic Advisors first reported a position in Rocket Pharmaceuticals in Q1 2018 and has held it in 22 quarters since.
  • Schonfeld Strategic Advisors's Rocket Pharmaceuticals position peaked at $2.74M in Q2 2019.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.